Navigation Links
Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
Date:3/10/2009

'Trial Meets Primary and Key Secondary Endpoints'

NEW YORK, March 10 /PRNewswire/ -- Intra-Cellular Therapies, Inc. today announced the final results from the ITI-007 Phase II trial in patients with Sleep Maintenance Insomnia (SMI). In this study, ITI-007 significantly and dose-dependently increased slow wave sleep and decreased the duration of wake after sleep onset as measured by polysomnography (PSG), meeting the prespecified primary and key secondary endpoints of the trial. ITI-007 also increased total sleep time and sleep efficiency. PSG improvements such as increased total sleep time and slow wave sleep are associated with reports of improved sleep quality. Improvement in these sleep parameters is driven by the unique pharmacology of ITI-007 that can act simultaneously as a 5HT2A receptor antagonist, dopamine receptor phosphoprotein modulator (DPPM), and inhibitor of serotonin reuptake. These additional actions clearly differentiate ITI-007 from other sleep modulating drugs. The present Phase II data suggest the beneficial effects on sleep are a result of ITI-007's distinctive neuropharmacological mechanisms beyond simple 5HT2A receptor antagonism. As such, ITI-007 represents a novel approach for the treatment of insomnia characterized by difficulty in staying asleep, as well as for the treatment of insomnia related to psychiatric and neurologic disorders. These clinical results will be presented at a major scientific meeting in June.

"We are excited to have demonstrated ITI-007's ability to produce such robust improvements on sleep quality," stated Sharon Mates, Chief Executive Officer of Intra-Cellular Therapies. "We believe that the positive effects on sleep in this study are a result of ITI-007's unique pharmacological profile that clearly differentiate it from currently available sleep inducing or sleep maintaining drugs. These data set the stage for further investigation of ITI-007's ability to improve slee
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
3. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
4. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
5. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
6. Old and new therapies combine to tackle atherosclerosis
7. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
8. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
9. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
10. Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., , , , , , , , , ... , , AUDIO: , A team of scien... University of Arizona, Cold Spring Harbor Laborat...ing the DNA of corn. The... , , C... , , , , , , , ...
(Date:11/20/2009)..., , SEATTLE, Nov. 20 /PRNewswire-FirstCal...announced that the U.S. Food and Drug Administrati... Company,s amended Biologics License Application (...te response. The FDA has assigned a Prescription ...which time it will respond to Dendreon,s amended B...
(Date:11/20/2009)..., , SEATTLE, Nov. 20 /PRNewswire-First... MTA: CTIC) announced today that the Ninth Circuit...rder and ruled that CTI should be allowed to pursu...g the case back to the District Court for trial. ...s former third-party reimbursement consultant for ...
(Date:11/19/2009)..., , Most people would like to be able to charge t...ickly and not too often. A recent discovery made b...tube-based supercapacitors that could do just this...hysics Letters , Prabhakar Bandaru, a professor in...ngineering, along with graduate student Mark Hoefe...
Breaking Biology Technology:Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Nanotube defects equal better energy and storage systems 2
...Research Firm,s Services and ...ciQuest, Inc., the global leader,in helping academ...realize,the potential of strategic procurement, to... biopharmaceutical research and development,compan...automate,procurement functions for each of its mor...
...Group plc (AIM:,PRG), the international pharmaceut...s, Inc., a leader in the electronic transformation...day announce the formalization of a,partnership ag...new partnership combines Octagon,s expertise in el...sive clinical expertise across a,wide array of the...
...nal is a leader,in vision healthcare -- serving pe...ed for 103 years., According to Dr. Tara A Cortes... "This is a dramatic breakthrough in gene therapy ...seases that affect children.", According to Yocas...nal,who has Leber,s Congenital Amaurosis and whose...
Other Biology Technology:Array BioPharma Selects SciQuest to Automate Procurement and Enable Agile Drug Development 2Premier Research Group plc and Octagon Research Solutions, Inc. Announce Strategic Partnership 2
(Date:11/22/2009)..., Census of Marine Life scientists have inventori...ution of deep sea species that have never known su... a frigid black world down to 5,000 meters (~3 mil...towed cameras, sonar and other vanguard technologi...arkness now number 17,650, a diverse collection of...
(Date:11/22/2009)..., Cambridge, MA November 23, 2009 Agios Pharmac...established, for the first time, that the mutated ...ith a cancer-causing gene, or oncogene. This break...DH1 produces a metabolite, 2-hydroxyglutarate (2HG...nant progression of gliomas, the most common type ...
(Date:11/20/2009)..., NJIT researchers are at work on many scientific... Foundation has recently provided support that tot... the following investigators under the American Re...searchers have been awarded grants for investigati...hed professor of physics, will enhance the capabil...
Breaking Biology News(10 mins):Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 3Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 4Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 5Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 6Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 7Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 8Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 9Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 3Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 4NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Standard 26amp 3B Poor 26apos 3Bs Upgrades Wellmont Outlook 55325 1Standard 26amp 3B Poor 26apos 3Bs Upgrades Wellmont Outlook 55325 2Standard 26amp 3B Poor 26apos 3Bs Upgrades Wellmont Outlook 55325 3Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 1Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 2Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 3Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 4Saliva May Help Spot Oral Cancer Early 55317 1Saliva May Help Spot Oral Cancer Early 55317 2
...importance nowadays since it express who we are, b... individual from its form? The answer to that ques...et a group of scientists from the Universidad Naci...the USA, were able to address it, although motivat...he capacity to establish the function of a molecul...
... Health Organisation (WHO) has confirmed a low fre... 3 influenza seasons (2003 ?2006)1. , The infor...usceptibility Network in the WHO’s Weekly Epidemio...und 0.3% to oseltamivir was seen during the influe...amiflu use in Japan (35 million patients), the hig...
...apillomaviruses responsible for genital warts was ...lian of the Year 2006 Professor Ian Frazer and tri...ine , More than 200 patients in China and Austral...e Princess Alexandra (PA) Hospital. , "The new ...now if it improves the outcome after conventional ...
Other Biology News:WHO data confirms low level of resistance to Tamiflu 2WHO data confirms low level of resistance to Tamiflu 3
...XPRESS 2D Proteomic Imaging System, Professional P...n Over a Wide Dynamic Range: The ProXPRESS 2D Prot...ing system for both proteomic and general life sci...unparalleled flexibility, enabling the use of all ...
... T2-01 high-performance pump, available in a singl... efficiency dynamic valve design. With the most co...e, T2-01 is ideal for use in portable air and gas ... (T2-01 SH and T2-01TH). , Delivers 1.5 and 2.0 li...
...cription: ,Kit containing Dermal Fibroblasts (rab...taining 20% FBS and 10% DMSO at passage 25 (approx...This cell culture is supplied as a long-term cultu...onths of continuous growth from the date supplied,...
... containing Vaginal Keratinocyte Progenitors, Rabb...aining 20% FBS and 10% DMSO at passage 25 (approx)...his cell culture is supplied as a long-term cultur...nths of continuous growth from the date supplied, ...
Biology Products: